IntuitionLabs

INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

Pharma AI Infrastructure: 2026 Deals and Investments

> Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-04-10 · pharma ai · ai infrastructure · drug discovery · pharmaceutical r&d · gpu computing · biotech funding · machine learning

Original article: https://intuitionlabs.ai/articles/pharma-ai-infrastructure-investments



In this article

1. Executive Summary
2. Introduction and Background
3. The Rise of AI in Pharmaceutical R&D: Historical Context
4. Early Computational Methods
5. Big Data and Machine Learning
6. Deep Learning and the Modern AI Wave
7. Economic & Strategic Drivers
8. Current State of AI in Pharma
9. Lilly–NVIDIA Co-Innovation Lab
10. Announcement and Overview
11. Technical Infrastructure: LillyPod and Beyond
12. Earendil Labs and \$787M Funding
13. Company Profile: AI-Driven Biologics Discovery
14. Details of the \$787M Aggregate Financing
15. Earendil's Technology and Pipeline
16. Strategic Implications and Analysis
17. Big Pharma's AI Infrastructure Bet
18. Examples of AI Factories in Pharma
19. Rationale for the "Infrastructure Bet"
20. Adoption and Workforce
21. Market and Data Analysis
22. Case Studies and Examples
23. Regulatory and Ethical Considerations
24. AI Partnerships and Ecosystem Trends
25. Implications and Future Directions
26. Conclusion
27. References

Executive Summary

This report examines the recent surge of **AI-driven deals and infrastructure investments in the pharmaceutical industry**, covering developments announced through April 2026. We analyze three major areas:

1. **The Lilly–NVIDIA Co-Innovation Lab:** In January 2026, Eli Lilly and NVIDIA announced a landmark $1 billion co-investment over five years to create an **AI-focused drug discovery lab** (investor.lilly.com) (www.linkedin.com). This partnership combines Lilly's deep pharmaceutical expertise with NVIDIA's cutting-edge AI hardware and software (including the NVIDIA BioNeMo platform and Vera Rubin GPU architecture) (investor.lilly.com). The lab is intended to co-locate biologists, chemists, and AI engineers in the San Francisco Bay Area, creating a **24/7 continuous learning loop** that tightly integrates "wet-

lab" experiments with "dry-lab" simulations. Key infrastructure includes *"LillyPod,"* the world's first NVIDIA DGX SuperPOD for a pharma company (www.linkedin.com) (investor.lilly.com), delivering over 9,000 petaflops of compute power. This makes Lilly one of the first and most powerful adopters of AI supercomputing in drug R&D. We detail the lab's objectives (accelerating molecular hypothesis testing, developing foundation models for chemistry and biology, robotics use in labs, digital twins for manufacturing, etc.) and discuss its strategic significance in the broader AI-in-pharma "arms race."

2. **Earendil Labs' $787M Financing:** In March 2026, Earendil Labs (a U.S.-incorporated, Beijing-headquartered **AI biotech startup**) announced aggregate financing of $787 million across financing rounds (Earendil issuer release). This marks one of the largest raises ever for an AI biotech. Earendil specializes in **AI-driven biologics discovery**, particularly for autoimmune and inflammatory diseases. Its AI "production engine" has already generated 40+ biologic drug programs (e.g. an anti-TL1A antibody HXN-1001 entering Phase II) (www.biospace.com) (www.chemdiv.com). We explore how this funding will massively scale Earendil's R&D organization and pipeline, its strategic collaborations with Sanofi (including multi-billion-dollar licensing deals on bispecific antibodies) (www.pharmalive.com) (www.biospace.com), and the implications for Eastern and Western biotech ecosystems. We also discuss the reported consideration of a Hong Kong IPO in 2026 (www.bloomberg.com), as well as how Earendil exemplifies the trend of **"AI-first" biotech** startups attracting huge capital commitments.

3. **Big Pharma's AI Infrastructure Investments:** Beyond specific deals, the industry trend is that **large pharmaceutical companies are racing to build out AI computing infrastructure**. Companies like Roche, Lilly, GSK, and Mitsui are constructing massive GPU-powered "AI factories" for drug R&D. For example, Roche expanded its global AI cluster by adding **2,176 NVIDIA Blackwell GPUs** in March 2026, bringing its total to over 3,500 GPUs – the largest announced deployment in pharma (www.roche.com). Likewise, Lilly's new LillyPod (1,016 GPUs) is now among the most powerful on-prem supercomputers in life sciences (www.linkedin.com). We compare known deployments (e.g. the UK's Cambridge-1 with 640 NVIDIA A100 GPUs (nvidianews.nvidia.com), Japan's Tokyo-1 with 128 H100 GPUs (www.datacenterdynamics.com)) and show how these buildouts signal an **"AI arms race"** in pharma. We examine the rationale: as the Biopharma industry faces patent cliffs (up to $230B in sales by 2030 (www.chemdiv.com)) and high R&D failure rates, executives see AI as necessary to unlock new discovery value and cut costs (www.deloitte.com) (www.chemdiv.com). We also cover how cloud giants (AWS, Microsoft, Google) are adapting to life sciences needs (GxP compliance, data security) in parallel (business20channel.tv). Overall, this section synthesizes multiple deals and announcements to illustrate how big pharma is translating AI hype into concrete infrastructure bets, and we analyze the competitive and economic implications.

Throughout, we provide **extensive evidence and data**: investment figures, GPU counts and computational capacity, market forecasts, survey results, and quotes from industry leaders. We consider different perspectives, including business strategy (e.g. ROI, competitive advantage), scientific impacts (faster discovery through modeling and simulation), and broader policy/ethical issues (regulatory guidances, data privacy, biosecurity concerns). Numerous case studies (like AlphaFold, AI-discovered drug candidates, Exscientia's algorithms, etc.) and statistics (AI market size, R&D spending, VC funding trends) are leveraged.

Tables summarize key metrics (see Tables 1 and 2 below). We conclude with a discussion of future directions – from fully autonomous " agentic AI scientists" to ethical frameworks – and reflect on how these developments through April 2026 fit into the transformative trajectory of pharma R&D.

Introduction and Background

The 2020s have seen **artificial intelligence (AI)** emerge as a transformative force across industries – with perhaps the most profound potential being in healthcare and pharmaceuticals.For decades, drug discovery has been a laborious, expensive endeavor: it often takes over a decade and upward of $2 billion to bring a new drug to market (www.deloitte.com), and the success rate is notoriously low (approximately 90% of drug candidates fail in clinical trials). The pharmaceutical industry invests hundreds of billions in R&D annually (global R&D spending in pharma is on the order of $200–250 billion (www.statista.com)) in hopes of reversing these odds, but innovation has plateaued in many therapeutic areas. Meanwhile, the explosion of biomedical data – from high-throughput genomics to real-world health records – presents opportunities only AI can manage.

Recent advances in AI promise to **revolutionize drug discovery** by compressing timelines, exploring vast chemical and biological spaces, and enabling knowledge previously inaccessible to humans. Methods such as deep learning and large language models (LLMs) have found new applications in chemistry, protein folding, molecular simulation, and literature mining. Landmark breakthroughs illustrate the trend: Google DeepMind's AlphaFold in 2020 achieved near-perfect protein structure prediction, a "gift to humanity" that dramatically accelerates understanding of biological targets (www.axios.com). In mid-2024, AlphaFold3 further extended the paradigm by predicting interactions among diverse molecular species (DNA, RNA, small molecules), "opening roads to new drugs" (www.axios.com). Generative models can now propose novel molecular structures optimized for desired properties (e.g. potency, safety), while computer vision is automating histology and lab monitoring. These capabilities are no longer theoretical: several pharmaceutical products are already in development with AI-derived designs.

Given this backdrop, the developments covered through **April 2026** illustrate pharma leaders' growing investment in AI. Big Pharma and Big Tech are converging: NVIDIA, maker of the world's leading AI hardware, has become a common partner for companies like Roche, Lilly, and GSK. Lilly's $1B co-innovation lab with NVIDIA was unveiled in January 2026 (investor.lilly.com), while Roche scaled up its NVIDIA-powered "AI factory" in March 2026 (www.roche.com). Virtually overnight, these drug companies claim to operate the largest supercomputers in the industry. Simultaneously, hundreds of millions in venture funding (Earendil's $787 million in aggregate financing (www.biospace.com) being a prime example) flow into specialized AI-biotech startups aimed at making drug discovery more "data-driven" at every step.

This report provides an **in-depth analysis** of these developments. We begin by situating the reader in the broader history and data of AI in pharma R&D (Sections 2–3), covering technological foundations (machine learning, deep learning, generative AI, simulation, etc.) and economic pressures (patent expirations, rising R&D Costs). Next, we examine *specific deals*:

- **Section 4:** *The Lilly–NVIDIA Co-Innovation Lab*, including technical details (BioNeMo, robotics, "wet lab/dry lab continuum"), strategic aims, and related infrastructure (LillyPod, LillyTuneLab).

- **Section 5:** *Earendil Labs and the $787M Financing*, profiling this startup's model, pipeline, investor syndicate, and how it fits into Sanofi/Pfizer's strategy and the larger trend of AI-biotech funding.
- **Section 6:** *Big Pharma's AI Infrastructure Buildout*, surveying other industry moves (Roche, Mitsui, NVIDIA Cambridge-1, etc.), summarizing GPU deployments (see Table 2), and discussing why giants are now spending on "AI factories."

We interweave **case studies** of AI use in drug discovery (from internal R&D examples to external successes like Exscientia's AI-guided compounds) and **data/statistics** on the AI-pharma market (growth projections, funding figures, adoption rates) to support our analysis. Throughout, each claim is annotated with citations to press releases, industry reports, academic articles, and authoritative news. Technical details (e.g. GPU performance) are cited from sources like NVIDIA press releases (www.linkedin.com) (www.roche.com) and industry news (www.datacenterdynamics.com). We also present quotes from company executives and experts to illustrate motivations.

The aim is comprehensive: this report is written in an academic/whitepaper style, with sharp historical context (how did we get here?), thorough coverage of the current state, and forward-looking discussion of implications (Section 7). We contrast perspectives where relevant – e.g., the techno-optimism of AI proponents vs. cautionary notes about hype and risk. We highlight how global regulatory bodies (e.g. FDA) are moving toward new guidelines for AI in drugs (draft guidances in 2025) (www.fda.gov), and touch on ethics (data privacy, dual-use concerns (www.frontiersin.org)). Finally, we conclude by synthesizing the key lessons: the deals covered through April 2026 are not isolated events but emblematic of the "AI-driven transformation" of pharma, with both enormous promise and significant challenges ahead.

All claims are fully backed by sources: news reports, press statements, conference analyses, and peer-reviewed research where available. For ease of reference, we include two summary tables: **Table 1** lists major pharma–AI partnerships (partners, announcement dates, investment amounts), and **Table 2** catalogs leading AI compute platforms in pharma (companies, GPU counts, performance, etc.). These serve as quick references to the scale of the commitments.

The Rise of AI in Pharmaceutical R&D: Historical Context

Before examining the latest deals, it is essential to understand the broader context of **AI's evolution in drug discovery**. Traditional pharmaceutical R&D has long leveraged computational methods (e.g. molecular modeling, QSAR, bioinformatics), but the recent decade has seen an exponential expansion of AI capabilities and data availability.

Early Computational Methods

Drug discovery has always involved computation to some extent. As early as the 1980s and 1990s, companies used:

- **Molecular docking and virtual screening:** Early software could virtually “screen” millions of compounds against protein structures, using physics-based models.
- **Quantitative structure–activity relationship (QSAR):** Statistical models correlating molecular features with biological activity.
- **High-performance computing (HPC) simulations:** Limited supercomputers (e.g. in national labs) were sometimes used for molecular dynamics (MD) simulations of proteins.

However, these methods had severe limitations. Physics-based simulations of drug-target interactions were extremely costly in time and resources, limiting them to small-scale problems. Statistical models (QSAR) required careful feature engineering and struggled with the immense chemical space (estimated at 10^60 possible drug-like molecules). Early artificial neural networks (1990s AI) had limited success due to small datasets and hardware.

Big Data and Machine Learning

The 2000s brought large-scale genomics, electronic health records, and faster computing. Machine learning (ML) techniques (support vector machines, random forests, etc.) entered pharmaceutical R&D in many guises:

- Bioinformatics (e.g. identifying gene-disease associations).
- Image analysis (digitizing pathology slides).
- Safety predictions (ADMET modeling).
- Clinical trial optimization (patient stratification).

Yet, none of these constituted a “revolution” in drug discovery; they largely supplemented existing processes. In many cases, ML models improved sub-tasks (e.g. predicting toxicology) but drug development still relied heavily on chemistry intuition and trial-and-error. R&D productivity (drugs per R&D dollar) continued to decline through the 2010s, emblematic of what some call “Eroom’s law” (the inverse of Moore’s law: drug discovery costs double about every nine years).

Deep Learning and the Modern AI Wave

The “modern AI era” began around 2012 with deep neural networks achieving breakthroughs in image recognition, natural language processing, and games. In parallel, pharmaceutical data expanded (structural biology data, PubMed publications, high-throughput screening results, etc.). This convergence gave rise to **deep learning and generative models in pharma**:

- **DeepChem and Cheminformatics:** New tools represented molecules as graphs or strings (SMILES) fed into neural networks. Deep learning often outperformed traditional ML in property prediction.
- **AlphaFold and protein folding (2020):** DeepMind’s AlphaFold2 astonished biology by solving protein folding at scale (www.axios.com), radically accelerating structural biology.
- **Generative Models (2019–2021):** Variational autoencoders, GANs, and later Transformer/LLMs applied to molecules (e.g. GPT-style models generating new compounds).
- **Natural Language Processing (NLP):** Models like BioBERT scanned biomedical literature to extract knowledge on targets, mechanisms, and clinical outcomes.

- **Systems biology and multiomics:** Integrating genomic, proteomic, and clinical data with AI to identify disease drivers.

Key breakthroughs included projects where AI-designed molecules moved into trials. For example, on January 30, 2020, **Exscientia** and Sumitomo Dainippon Pharma announced that a Phase I clinical study of the AI-created candidate DSP-1181 had been initiated in Japan, with obsessive-compulsive disorder as the initial indication (joint announcement). **Insilico Medicine** similarly reported molecules entering preclinical testing via AI design. These cases validated the concept that AI could replace or drastically accelerate parts of the discovery pipeline (wifitalents.com) (www.chemdiv.com).

Pharmaceutical companies have pursued AI collaborations for years: Novartis announced its AI innovation lab and selected Microsoft as its strategic AI and data-science partner on October 1, 2019 (Novartis announcement). Both internal pilot projects and external partnerships proliferated, as summarized in industry reports (e.g. 168 AI-related collaborations in 2025 alone, per GlobalData (www.chemdiv.com)).

Economic & Strategic Drivers

The historical lag in productivity (Eroom's law) created urgency. Major patent expirations (so-called "patent cliffs") loomed: between 2025 and 2030, about $230 billion in branded drug sales in the U.S. are at risk of generic/biosimilar competition (www.chemdiv.com). To replace revenue, companies need breakthrough new drugs. Traditional R&D methods are too slow and expensive to fill these gaps. AI promises a means to reaccelerate innovation:

- **Faster discovery:** AI can screen vast virtual libraries instantly. Rather than testing ~2,000 molecules per target per year in wet labs, companies can now simulate **billions** of hypotheses in silico (www.linkedin.com).
- **Reduced costs:** By weeding out unpromising candidates early, AI can reduce expensive wet-lab experiments.
- **New mechanisms:** AI can reveal hidden patterns or bio-pathways that humans might miss, potentially enabling first-in-class therapies.
- **Longer tail of innovation:** Automating mundane analytics frees scientists to focus on creativity, shifting pharma's culture toward more exploratory R&D.

Executives from major firms recognize this: at Davos 2025, Takeda CEO Christophe Weber said becoming a "digital biopharma company" requires harnessing big data and AI across the entire value chain (www.axios.com). Likewise, reports forecast huge market impacts. For example, Deloitte models a conditional opportunity for a top-10 biopharma company with average revenue of $65–75 billion to capture $5–7 billion in peak value by scaling AI over five years (Deloitte report). Other analysts predict the global market for AI in drugs will reach tens of billions in the next decade (wifitalents.com) (www.deloitte.com). Such figures, while optimistic, underscore management mindsets: AI investments are not just R&D experiments but strategic bets on transforming the core business.

Current State of AI in Pharma

By early 2026, AI in pharma has moved beyond pilot projects to **enterprise-scale implementation**. Key characteristics:

- **AI and ML integrated at multiple stages:** From target identification (via genomics data mining) to lead optimization (predicting ADMET properties of molecules) to clinical trial design (patient selection models). Machine learning aids patient stratification based on real-world data, even administrative tasks like contract analysis through AI summarization.
- **AI-specialized biotech startups:** Companies like Recursion, Valo Health, BenchSci, BenevolentAI raised hundreds of millions to focus on AI pipelines or data platforms. This creates an ecosystem where Big Pharma often partners (or acquires) these nimble players to augment internal R&D.
- **High-performance AI infrastructure:** Unlike earlier reliance on cloud or specialized smaller clusters, pharmaceutical companies are now building *their own* AI compute environments – often more powerful than cloud instances for large-scale model training and simulations.
- **Commercial tools and platforms:** New software frameworks (e.g. NVIDIA's BioNeMo, Microsoft's Bio-AI offerings) are tailored to life sciences. Platforms for federated learning are emerging to allow confidential multi-institution collaborations.
- **Regulatory attention:** U.S. FDA and other agencies are drafting rules for validated use of AI/ML in drug dev and manufacturing, recognizing models can inform decisions (some draft guidances in 2024-25 on AI credibility) (www.fda.gov).
- **Global dimension:** Asia is rapidly embracing AI-pharma. China has many AI biotech startups (such as Earendil) and significant venture funding, while Japan's Mitsui and Korean pharma jointly invested in AI supercomputers (www.datacenterdynamics.com).

In sum, by April 2026 we stand at an **inflection point**: AI methods have proven out beyond proof-of-concept, and both startups and incumbents see tangible outputs. The stage is set for deeper investments – hence the significance of the two deals detailed below, and the broader industry movement we analyze.

Lilly–NVIDIA Co-Innovation Lab

Announcement and Overview

On January 12, 2026, at the J.P. Morgan Healthcare Conference, **Eli Lilly and NVIDIA** publicly unveiled a first-of-its-kind **AI co-innovation laboratory** for drug discovery (investor.lilly.com). In a news release, the companies announced they would **jointly invest up to $1 billion over five years** in infrastructure, talent, and computing resources to tackle "the hardest problems in drug discovery" (investor.lilly.com). The lab will be physically located in the San Francisco Bay Area and aims to tightly integrate biologists, chemists, and AI researchers on a single campus (investor.lilly.com).

Key elements of the announcement include:

- **Investment:** Up to $1 billion over five years, covering hardware, software, and personnel (investor.lilly.com).
- **Platforms:** Use of the **NVIDIA BioNeMo platform** (AI foundation models for life sciences) and **NVIDIA Vera Rubin** GPU architecture (investor.lilly.com).
- **Talent:** Co-locating 100+ scientists from Lilly (biology, chemistry, pharmacology) with NVIDIA's top AI modelers and engineers (investor.lilly.com).
- **Compute:** Leveraging Lilly's existing AI supercomputer (the most powerful in pharma, announced in late 2025) and continuing to expand it (investor.lilly.com) (www.linkedin.com).
- **Technology:** Emphasis on robotics and "physical AI" to create an end-to-end "lab-in-the-loop" where automated experiments feed data back to AI and vice versa (investor.lilly.com) (www.linkedin.com).
- **Platforms to share with partners:** Lilly noted that its internal AI platform (Lilly TuneLab) will offer biotech partners access to proprietary models, while NVIDIA's FLARE federated learning tech will ensure data privacy (www.linkedin.com).

The companies characterized the lab as a **new "blueprint" for drug discovery**. NVIDIA CEO Jensen Huang stated, "NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made." (investor.lilly.com). Lilly CEO David Ricks similarly emphasized that combining Lilly's "volume of data and scientific knowledge with NVIDIA's computational power" could "reinvent drug discovery as we know it" (investor.lilly.com).

These statements echo a broader narrative: Lilly and NVIDIA claim that the constraints of traditional R&D (wet-lab bottlenecks, limited throughput) can be overcome by dissolving the barrier between physical experiments and AI-driven simulation. The lab is described as building a **"continuous learning system"**, in which experiments, data generation, and model training constantly inform each other (investor.lilly.com).

Context: While this formal announcement was in Jan 2026, it builds on prior work. As Lilly notes, it already has the most powerful AI factory in pharma (its AI supercomputer unveiled in late 2025 (investor.lilly.com); see below). The co-lab essentially formalizes and scales up existing Lilly/NVIDIA collaborations under a high-profile initiative, aligning with trends at other companies (e.g. Roche's ongoing NVIDIA partnership (www.roche.com)).

Technical Infrastructure: LillyPod and Beyond

The news release mentions Lilly's "AI factory" from late 2025 (investor.lilly.com), which was reported elsewhere as the *LillyPod*. According to an industry bulletin (www.linkedin.com), LillyPod is a **NVIDIA DGX SuperPOD** outfitted with **1,016 NVIDIA Blackwell Ultra GPUs**, delivering over **9,000 petaflops** of AI performance (www.linkedin.com). (For comparison, this beats most academic supercomputers). Table 2 (below) summarizes LillyPod alongside other pharma AI clusters.

This GPU farm is the *largest AI system owned by any pharma company* (www.linkedin.com). It was assembled in just four months and is said to remove the "fundamental physical constraint" of wet labs: whereas a human lab can test a few thousand molecules a year per target, LillyPod allows simultaneous evaluation of **billions of**

molecular hypotheses via simulation (www.linkedin.com). In practice, Lilly scientists can run ultra-fast molecular docking, quantum chemistry, and even multi-step lab robotic instructions within the pod's compute, drastically expanding the search space for drug candidates.

Lilly's lab also integrates **Lilly TuneLab**, an AI/ML platform trained on Lilly's vast proprietary data (estimated over $1B worth, in terms of collected R&D data). TuneLab will be open to Lilly's collaborators, offering them access to Lilly's specialized drug-discovery models (www.linkedin.com). Importantly, this platform is built on NVIDIA's BioNeMo (a collection of pretrained foundation models for chemistry and biology) and uses federated learning (NVIDIA FLARE) to allow partners to benefit from Lilly's data-driven models without sharing sensitive data directly (www.linkedin.com). This approach suggests Lilly is not just hoarding AI internally but creating an ecosystem.

Beyond compute, the co-lab will invest in **robotics and physical AI**. The press release references NVIDIA Omniverse and RTX servers being used to create **digital twins** of Lilly's manufacturing lines (investor.lilly.com). This means performing simulations of pharma production processes (mixers, bioreactors, etc.) in the metaverse-style Omniverse platform to optimize yield and robustness before actual changes. The lab will also apparently apply AI to **manufacturing and supply chain**. Thus, while the headline is "drug discovery", NVIDIA and Lilly see broader applications (medical imaging, PK/PD modeling, clinical ops automation) (investor.lilly.com).

BioNeMo and Vera Rubin: The mention of BioNeMo (NVIDIA's bioscience AI platform) (investor.lilly.com) implies the lab will leverage pre-built foundation models (e.g., large protein-LM, molecule-LM, multiomics-LM) rather than starting from scratch. The partners plan to base their new lab on BioNeMo software and Vera Rubin hardware (NVIDIA co-innovation announcement). LillyPod uses NVIDIA DGX B300 systems (NVIDIA LillyPod launch).

The Lilly news release and related coverage emphasize that this lab concretely ties AIs to lab work: experiments produce training data and model predictions generate experiment suggestions in a loop (investor.lilly.com). This scientist-in-the-loop framework is a novel vision for R&D: an autonomous "AI scientist" model being teased in robotics/drug literature. NVIDIA and Lilly even coined the term *"physical AI"* and *"agentic wet labs"*, indicating robots or lab automation controlled by AI agents might perform bench work continuously (investor.lilly.com) (www.linkedin.com).

Finally, the lab will explore applications beyond discovery, including clinical trials design and commercial analytics (investor.lilly.com). NVIDIA Omniverse and RTX are highlighted as tools for "digital twins" in manufacturing and supply logistics (investor.lilly.com). All told, this lab initiative ties together Lilly's data and domain expertise with NVIDIA's hardware/software stack (chips, libraries, SDKs) to create a 360° "AI factory" for pharma.

Quotes and Analyst Commentary

Media accounts (e.g. FierceBiotech) and industry analysts noted that this **$1B Lilly-Nvidia lab** is an unusually large commitment, underscoring how seriously pharma is now taking AI (investor.lilly.com). For example, FierceBiotech reported that Lilly's and NVIDIA's stocks had both risen on the news, reflecting investor enthusiasm. The partnership was compared to the 2020's cloud-and-AI deals (e.g. Novartis-Microsoft, GSK-Cloud-1 project) but on an even grander scale given Lilly's fully owned infrastructure.

In interviews, NVIDIA's Jensen Huang and Lilly's Dave Ricks have highlighted that the scale of compute needed to innovate in biology is akin to building a new industry-wide AI infrastructure (investor.lilly.com) (www.linkedin.com). Some commentators label this the emergence of a **"pharma AI factory"** paradigm (mirroring the "AI factory" concept used in industry), where pharmaceutical innovation is driven by data and compute as much as by chemistry intuition. The co-investment lab is literally a meeting of those worlds.

However, some analysts caution that execution remains to be seen: building models is one thing, turning them into effective drugs is hard. Drug discovery is notoriously non-linear; biology is complex and often data-poor. Skeptics point out that past high-profile AI ventures (e.g. IBM Watson for oncology) have disappointed. The lab's success will depend on integration: will biologists effectively use the AI models (or vice versa)? Metrics for success are unclear. But nearly all industry observers agree this is a **bold bet**: Lilly is spending big on compute to avoid being outpaced by competitors, and NVIDIA is cementing its position in life sciences.

Relation to LillyPod and "AI Factory"

As noted in Section 2, Lilly's own AI supercomputing "factory" was already the most powerful in pharma prior to January 2026 (investor.lilly.com) (www.linkedin.com). Lilly's press release iterates that the new lab will **build on that factory**. Indeed, the lab's co-location is expected to materialize by late Q1 or Q2 2026 (four months after announcement (www.linkedin.com)). The supercomputing and AI models from LillyPod will serve as the **computational heart** of the lab.

To clarify these terms, we reproduce in Table 1 a summary of key entities and infrastructure related to the deal:

Initiative	Announced	Investment / Compute	Description	Source
Lilly–NVIDIA Co-Innovation Lab	Jan 2026	$1B over 5 years	AI lab (Bay Area) co-locating Lilly scientists and NVIDIA engineers to build AI-driven drug discovery. Continuous wet/dry lab integration using NVIDIA BioNeMo and Vera Rubin technologies (investor.lilly.com) (www.linkedin.com). Varying HQ models (Lilly TuneLab, Omniverse, etc.).	(investor.lilly.com) (www.linkedin.com)
LillyPod (AI compute)	Late 2025	1,016 NVIDIA Blackwell GPUs	World's first NVIDIA DGX SuperPOD wholly owned by a pharma. Powers Lilly's AI R&D (foundation model training, simulations) (www.linkedin.com).	(www.linkedin.com)
Roche–NVIDIA AI Factory	Mar 2026	+2,176 NVIDIA Blackwell GPUs (total 3,500+)	Roche's expanded hybrid-cloud GPU cluster for R&D, diagnostics, manufacturing optimization (www.roche.com). Now largest known GPU footprint in pharma.	(www.roche.com)
NVIDIA Cambridge-1 (UK)	Jul 2021	640 NVIDIA A100 GPUs	UK's most powerful AI supercomputer for healthcare (80 DGX A100 systems) shared by GSK, AstraZeneca, NHS (nvidianews.nvidia.com). Supports multi-pharma research.	(nvidianews.nvidia.com)
Mitsui Tokyo-1 (Japan)	2023	128 NVIDIA H100 GPUs	Generative AI supercomputer (16 DGX H100 systems) focused on pharma for Japanese companies. Operated by Xeureka; supports multiple pharma.	(www.datacenterdynamics.com)

Table 1: Summary of major AI computing infrastructure initiatives in pharma (late 2021–2026). This illustrates the scale of investments: multiple thousands of GPUs, multi-petaflop supercomputers, each aimed at accelerating drug discovery.

Earendil Labs and $787M Funding

Company Profile: AI-Driven Biologics Discovery

Earendil Labs is a one-year-old biotechnology startup founded by Jian Peng (PhD) and headquartered in Beijing, though incorporated in Delaware (www.pharmalive.com) (www.biospace.com). It focuses on **biologics drug discovery** – specifically, designing antibodies, enzymes, and other protein therapeutics using AI. The company's name is a reference to a star in Tolkien lore; it emerged in early 2025 as a well-funded AI startup.

What sets Earendil apart are two factors:

1. **AI-Native Platform:** Earendil claims to use AI *across the full lifecycle* of biologics R&D (www.biospace.com) (www.chemdiv.com). This means generative models create protein sequences, optimization algorithms refine them, and advanced ML models predict their drug-like properties (affinity, stability, immunogenicity, etc.). Rather than manually evolving antibodies, Earendil's pipeline allegedly can fabricate novel antibodies in silico with desired targets and properties.
2. **Heavy Partnering with Pharma:** From inception, Earendil has struck deep partnerships with large pharma. In early 2025, Sanofi paid $125M up front (and up to $1.72B in milestones) for two bispecific antibody programs from Earendil (www.pharmalive.com). In January 2026, Earendil announced a further Sanofi collaboration with up to $160M in upfront and near-term payments tied to early program achievements, within a total potential value of up to $2.56B including upfront payments and development and commercial milestones, plus tiered royalties (issuer announcement).

Earendil publishes information about its technology and pipeline. It has a "more than 40 programs" pipeline (www.pharmalive.com) (www.biospace.com), targeting diseases from autoimmunity to cancer. The best-known candidate is **HXN-1001**, an anti-TL1A antibody engineered for half-life extension (www.chemdiv.com). TL1A is a novel target for inflammatory bowel diseases. On April 2, 2026, Earendil announced completion of enrollment in its Phase I trial in healthy volunteers in Australia and first-patient dosing in a Phase IIa trial in patients with ulcerative colitis (Earendil clinical update).

Earendil's Recent Deals

- **January 2026:** Under the collaboration announced on January 5, Earendil may receive up to $160M in upfront and near-term payments tied to early program achievements. The total potential value is up to $2.56B, including upfront payments and development and commercial milestones, plus tiered royalties (Earendil announcement). The companies had previously entered a license and collaboration agreement for two bispecific antibodies in April 2025 (Sanofi financial report).

- **March 2026:** On March 20, Earendil announced aggregate financing of $787 million across financing rounds (issuer announcement). Participating investors included Sanofi and the Biotech Development Fund created by Hillhouse and Pfizer.

Details of the $787M Aggregate Financing

Earendil's March 20 announcement describes $787 million raised across financing rounds (issuer announcement).

- **Investors:** The disclosed participants were Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and the Biotech Development Fund created by Hillhouse and Pfizer, alongside other existing and new technology- and healthcare-focused investors.
- **Use of Funds:** Earendil will use the proceeds to accelerate its AI platform, scale up interdisciplinary R&D teams, and advance its biologic programs (www.biospace.com). Specifically, the funding is intended to:
- **Scale AI R&D platform:** Expand computational resources and algorithms (bigger data, more models).
- **Grow staff:** Hire more scientists (protein engineers, AI experts, bioinformaticians) to move "multiple programs toward the clinic" (www.biospace.com).
- **Advance pipeline:** Move existing candidates through preclinical and early clinical milestones (multiple INDs planned in 2026-27 (www.biospace.com) (www.chemdiv.com)).
- **Partnerships:** Deepen strategic collaborations (like with Sanofi) to co-develop products globally (www.biospace.com) (www.chemdiv.com).

Jian Peng (CEO, an AI researcher by background) said: "AI is at the core of everything we do — not as a research tool, but as a production engine for real therapeutic programs." (www.biospace.com) He added that the new funds allow operating at a "fundamentally different scale" and advancing "multiple programs toward the clinic" concurrently (www.biospace.com) (www.chemdiv.com).

Co-CEO Dr. Zhenping Zhu emphasized the patient-centric focus: the funding "strengthens our ability to translate AI-enabled innovation into potentially transformative medicines" and will "accelerate our research and development programs worldwide" (www.biospace.com).

Dimension Capital's Zavain Dar (their message) praised Earendil's execution: "Earendil Labs stands out for its ability to translate AI innovation into real, scalable R&D execution… We are excited to support Earendil Labs as it builds a new paradigm for biologics discovery" (www.biospace.com). This underscores investor confidence that Earendil is beyond theory; it "has shown that AI can consistently generate high-quality biologics programs" (www.biospace.com).

Earendil's Technology and Pipeline

Earendil describes its technology and pipeline in company materials. Key points include:

- **AI Pipeline ("Engine"):** Described as "AI-driven platform that integrates artificial intelligence across the full life cycle of biologics R&D" (www.biospace.com). Likely components (inferred from industry norms) include:

- Generative models for antibody sequences (e.g. variational autoencoders or LLMs to create novel protein topologies).
- Neural predictors for binding affinity and developability (trained on large datasets of antibodies and receptors).
- Optimization loops (reinforcement or evolutionary algorithms) to improve lead candidates.
- Cloud or HPC infrastructure for protein folding simulations (possibly leveraging techniques like AlphaFold/AlphaFold2, or similar in-house models).
- **Pipeline Diversity:** The company claims 40+ internal programs. Reports highlight one “star” program, **HXN-1001**, a half-life extended anti-TL1A antibody for Crohn’s disease/ulcerative colitis (www.chemdiv.com). TL1A is a novel target (a TNF-like cytokine); presumably, Earendil’s AI generated an antibody with better potency or durability than human-designed ones. Additional programs are undisclosed but likely cover multiple autoimmune targets.
- **IP and Data:** Being Delaware-incorporated but Beijing-based suggests use of Chinese AI talent and computational resources, possibly with access to large Chinese biomedical datasets (one Bloomberg piece flagged its China ties (www.pharmalive.com)). Big data (proprietary and public) would feed into its AI training.
- **Comparison:** Earendil’s approach is similar in spirit to US-based **Absci**, which uses deep learning to design proteins, or to Exscientia but focused on biologics rather than small molecules. Earendil announced $787 million in aggregate financing across financing rounds. It signals a belief that **protein engineering via AI** can be scaled to an in-house drug factory.

Strategic Implications and Analysis

Earendil’s success in raising $787M (plus potential IPO) has multiple implications:

- **Validation of AI-Biotech:** Earendil announced $787 million in aggregate financing across financing rounds. Investors expect returns from licensing fees, milestones, or future IPO.
- **China’s Role:** Although the founders are Chinese and HQ in Beijing, the company has U.S. incorporation and Western backers (Sanofi, Pfizer). This hybrid model may accelerate cross-border tech transfer. It highlights China’s investment in biotech, while U.S. and European pharma are open to capitalizing on it.
- **Big Pharma Eyeing AI Partners:** Sanofi (and Pfizer indirectly) locking into Earendil’s platform demonstrates a trend where established pharma outsources or partners with AI novices instead of doing all R&D internally. It’s an “open innovation” model but powered by AI.
- **Pipeline Acceleration:** If Earendil’s platform works as claimed, expensive biologics like monoclonal antibodies could come to clinic 2–3 years faster than traditional methods. That could shift how quickly companies respond to disease needs.
- **IPO Prospect:** A Bloomberg report (Mar 13, 2026) indicated Earendil may pursue a Hong Kong IPO of up to $500M (www.bloomberg.com). Such a step (despite regulatory hurdles on gene-editing stock like Shenzhen) would allow earlier investor exits. It’s notable that the IPO might be in Asia, reflecting the company’s origins and perhaps strategic positioning against US regulatory nationalism.

- **Competition and Market:** Earendil's emergence puts pressure on competitors. Other AI biotech firms (e.g., Insilico, Recursion, etc.) also chase big deals. Traditional biotech (Amgen, J&J, etc.) will monitor these models closely to decide when to invest heavily or partner.

We also note **market context** from the ChemDiv report (www.chemdiv.com). It cites a GlobalData survey finding that 168 strategic alliances related to AI were signed in 2025, indicating a flurry of activity. It even mentions explicitly the Lilly/NVIDIA lab as one such deal, noting companies realize AI's "exponential" impact. According to analyst forecasts, up to 27% of pharma R&D dollars could be influenced by AI by 2035 (www.towardshealthcare.com) (from Mordor Intelligence). These numbers reinforce that Earendil's funding fits into a broader capital wave.

Finally, a key strategic benefit for Earendil's backers is pipeline breadth. Because Earendil has ~40 programs, Sanofi and Pfizer can secure rights to multiple potential drugs across several disease areas, rather than betting on just one. The milestone payments (billions at risk) show belief in at least a few of them making it far. If just one biologic reaches market, it could pay off the entire investment.

In conclusion, **Earendil's $787 million in aggregate financing** symbolizes the maturation of the AI-biotech startup model. It illustrates how a well-endowed AI platform company can become a linchpin between Big Tech advances and Big Pharma needs. Its execution over the next 5 years will be a case study in whether AI can truly "industrialize" biologics discovery as promised.

Big Pharma's AI Infrastructure Bet

The developments covered through April 2026 cannot be understood without recognizing that multiple Big Pharma companies are simultaneously making huge AI infrastructure investments. This section catalogs these moves and interprets their collective meaning as an industry bet on AI.

Examples of AI Factories in Pharma

Beyond Lilly's pod and Earendil's funding, several major announcements highlight the trend:

- **Roche** (Basel, Switzerland): On March 16, 2026, Roche announced it **expanded its AI computing** dramatically (www.roche.com). The company deployed an additional 2,176 NVIDIA Blackwell GPUs (on-premises across the US and Europe) to augment its already considerable computing infrastructure, bringing Roche's total to **over 3,500 GPUs** (www.roche.com). The press release touted this as "the pharmaceutical industry's largest announced hybrid-cloud AI factory." Roche explained this will speed up drug and diagnostics development, fuel AI across drug discovery (its Genentech "Lab-in-the-Loop" strategy) and manufacturing, and even power digital pathology. Executive Wafaa Mamilli said this expanded "AI factory" empowers Roche's workforce and shortens the path from biological insight to medicine (www.roche.com).
- **GlaxoSmithKline (GSK)** (London, UK): In 2021, NVIDIA launched **Cambridge-1**, a supercomputer with 80 DGX A100 nodes (≈640 A100 GPUs) delivering 408 petaflops (nvidianews.nvidia.com). It serves as a shared resource for GSK, AstraZeneca, academic and NHS researchers. Though older architecture,

Cambridge-1 is still among the world's fastest AI machines (its focus was broad AI research rather than a single pipeline).

- **Mitsui & Co. (Japan)**: In March 2023, Mitsui announced **Tokyo-1**, a NVIDIA DGX H100 cluster (16 DGX H100 systems = 128 H100 GPUs) dedicated to pharmaceutical R&D (www.datacenterdynamics.com). It is operated by Xeureka, a Mitsui subsidiary focused on AI-powered drug discovery (NVIDIA announcement). Tokyo-1 is notable for being Japan's first generative AI computer in pharma (www.datacenterdynamics.com) and it's made available to other Japanese drug companies (Astellas, Daiichi Sankyo, etc.) (www.datacenterdynamics.com), showing a national strategy.
- **Verily/J&J** (USA): In late 2025, news surfaced that J&J's medical technology unit and Verily (Alphabet's health subsidiary) inked deals with NVIDIA to deploy GPUs for surgical AI and other health applications (www.itpro.com). While not directly R&D of drugs, this shows even diversified health units are building AI compute with NVIDIA.
- **Novartis**: On October 1, 2019, Novartis announced its AI innovation lab and selected Microsoft as its strategic AI and data-science partner. The companies committed to a multiyear research and development effort (Novartis announcement).
- **IBM/Watson Health**: Historically, J&J and Pfizer had worked with IBM for AI diagnostics, but IBM has largely retreated from Watson Health by 2024 (so their HPC is not in forward strategy).

Table 2 (below) summarizes the known scale and architecture of these initiatives.

Organization / Initiative	GPUs (Architecture)	Compute (Approx.)	Purpose	Announcement Date	Source
Eli Lilly (LillyPod)	1,016 NVIDIA Blackwell Ultra	—	In-house AI drug discovery "factory"	Early 2026	(www.linkedin.com)
Roche Pharma AI Factory	3,500+ NVIDIA Blackwell	(Not specified)	Hybrid-cloud AI for R&D, diagnostics, manufacturing	Mar 2026	(www.roche.com)
NVIDIA Cambridge-1 (UK)	640 NVIDIA A100	—	Shared AI research for GSK/AZ/NHS (UK's most powerful AI SC)	Jul 2021	(nvidianews.nvidia.com)
Tokyo-1 (Mitsui, Japan)	128 NVIDIA H100	—	Generative AI for drug discovery (operated via Xeureka)	Mar 2023	(www.datacenterdynamics.com)
GSK's Cloud AI Services	(Cambridge-1 above, plus Azure)	—	Cloud and on-prem for R&D via partnerships with MSFT, AWS.	2022–2023	Industry reports

Table 2: Major AI computing platforms in pharma. "Compute" often given in petaflops (PF). Blackwell is NVIDIA's new architecture (successor to Hopper). Cambridge-1 and Tokyo-1 are dedicated SC projects. Lilly's and Roche's figures are from 2025–2026 announcements (www.linkedin.com) (www.roche.com).

Two points stand out: (1) **Scale** – these companies are deploying thousands of top-end GPUs, far beyond a single data scientist's workstation, even beyond what small biotech could afford. (2) **Strategy** – they are saying publicly that **computing power is a strategic asset** like labs and factories. Roche calls it a "supercomputing platform" for enterprise-wide transformation (www.roche.com). Lilly explicitly says its AI factory will handle

“modern scientific research using foundation models, physical AI, manufacturing, imaging etc.” (investor.lilly.com). In each case, leadership claims this will speed cures to patients by shaving years off development timelines.

Rationale for the “Infrastructure Bet”

Why is pharma investing so heavily, sometimes in-house and sometimes via partners, rather than completely outsourcing to cloud providers? Several motivations emerge:

- **Data Security and Integration:** Pharma companies hold vast proprietary datasets (e.g. patient records, trial data, historic compound libraries). Training advanced AI models often requires large data movement. Many companies prefer on-prem clusters or private clouds to keep data under control, ensure compliance with regulations (GDPR, HIPAA, etc.), and allow specialized security audits. For example, Lilly notes TuneLab will use federated learning to respect privacy (www.linkedin.com), but having on-site hardware means more control.
- **Performance and Scale:** For extremely large models (multi-billion parameter foundations) or massive simulation workloads, owning hardware (like a DGX SuperPOD) can be more cost-effective than renting cloud over years. The sheer size of LillyPod (1000 GPUs) suggests a workload too large to practically rent cloud time (especially at the high-performance interconnect needed). Latency and data-transfer issues also favor local systems for tight feedback loops between lab instruments and compute.
- **Competitive Advantage:** Having one’s own compute “moats” means a company can innovate faster than those relying solely on external services. It is somewhat analogous to owning manufacturing plants versus contract manufacturing – the former gives more control and potential efficiency later. Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development, said more compute allows scaling “Lab-in-the-Loop” AI and building more predictive models (www.roche.com). If one company discovers a target twice as fast as another, it wins product patent races.
- **Synergies with Cloud-AI Services:** Not all pharma is moving entirely on-prem. Many see a hybrid: big models trained on-prem, then tier-2 workloads or scaling done on AWS/Azure/GCP with healthcare-specific compliance layers (business20channel.tv). Some deals (e.g. Novartis/Microsoft) target exactly this mix. Yet the headlines are dominated by the *dedicated hardware*, because it’s novel and makes a media splash.

In summary, the **“AI infrastructure bet”** means pharma is treating strategic compute capability similarly to how tech companies do – a foundational layer for future products. This likely points to a future where *all pharma companies will have sizable AI clusters*, just as they have R&D centers and manufacturing plants. The risk is that those who cannot invest may fall behind or become outsourcing partners instead of leaders.

Adoption and Workforce

The shift to AI factories has also changed Pharma’s talent and processes:

- **New Roles:** Job postings have surged for “AI scientists” and “machine learning engineers” in pharma, reflecting that companies now need computational experts alongside biologists. The LinkedIn market bulletin noted NVIDIA and Lilly hired multidisciplinary teams for the lab. Internal training programs (like Lilly’s AI fellowship, or major pharma sponsoring AI courses) are becoming common.
- **Culture Change:** Companies emphasize cross-disciplinary labs. Lilly’s co-innovation lab is described as “startup environment” (investor.lilly.com) (despite being a corporate lab), indicating they want the agility of a tech startup. Roche’s “AI factory” is similarly positioned as a catalyst for a culture shift across the organization (www.roche.com).
- **Standardization:** As noted in the Business 2.0 report (business20channel.tv), many biopharma firms now focus on building internal frameworks for model validation, drift monitoring, and reproducibility. They borrow governance models from regulated industries: version control of models, audit trails, etc. This is partially in anticipation of regulatory requirements (FDA draft guidelines, see below).
- **Collaboration:** These investments also encourage more ecosystem collaboration. Lilly’s TuneLab federated approach is one example. Roche runs “AI Hackathons” with partners. In some countries, pharma companies share certain datatypes through consortia (e.g. the UK’s HDR UK initiative). NVIDIA’s Inception program and cloud AI credits further embed pharma into the tech ecosystem.

All told, Big Pharma’s **infrastructure bet** is not just hardware: it includes process engineering, workforce development, and partnership networks around AI.

Market and Data Analysis

To ground the above discussion in quantitative perspective, we analyze relevant data and market trends:

- **Market Size and Growth:** The global market for AI in pharmaceutical research is projected to grow at a CAGR of ~30-40% through the 2020s. According to industry reports, it may reach roughly **$6–12 billion by 2030** (various estimates). For instance, a 2026 analysis suggests the AI-driven drug discovery market could approach $11.8B by 2032 (wifitalents.com). Another estimate puts the broader AI in pharma market at $6.16B by 2026 (Mordor Intelligence) or even $60B by the mid-2020s (AllAboutAI) – though such numbers vary widely by definition (some include all AI in healthcare). Regardless, major consulting firms highlight multi-billion-dollar value: Deloitte models $5–7 billion in peak value for a top-10 biopharma company with average revenue of $65–75 billion, conditional on scaling AI over five years (Deloitte report).
- **R&D Spending Context:** Pharma companies collectively spent over $200B on R&D in 2024 (www.statista.com) (estimates vary). AI-driven approaches are still a small fraction of that, but by investing even a few percent (as Lilly did with $1B), companies hope to increase R&D efficiency. The potential to recover even a portion of failed R&D costs (often over 90%) by smarter discovery is driving the math.
- **VC Funding Trends:** Venture funding for AI-biotech startups spiked post-2020. For example, Earendil reported $787 million in aggregate financing across financing rounds (issuer announcement). A funding tracking site counted $2+ billion invested in AI drug discovery companies in 2025. According to

GlobalData (cited in chemdiv), 2025 saw **168 new strategic alliances** in pharma involving AI (www.chemdiv.com). This includes partnerships, not just funding; but on the venture side, some notable rounds:

- Insilico Medicine: announced $95M in aggregate Series D financing on August 10, 2022 (company announcement).
- Exscientia: announced a completed $225M Series D on April 27, 2021, plus a separate $300M equity commitment from SoftBank drawable at Exscientia's discretion (issuer release).
- Ginkgo Bioworks (less pharma-specific): huge IPO in 2021.
- Many smaller Series A/B deals for AI-biotechs (e.g. 1X Genomics, Cellarity, etc).
- **Adoption and Scaling:** In late summer 2024, McKinsey surveyed more than 100 pharma and medtech leaders responsible for their organizations' gen AI efforts. Its January 2025 article reports that all respondents had experimented with gen AI and 32% said they had taken steps to scale it (McKinsey survey).
- **Compute Scale:** The known GPU counts give an idea of scale. Table 2 lists totals of 128, 640, 1,016, and 3,500+ GPUs for new projects. Each high-end GPU (Blackwell or H100) delivers tens of teraFLOPS (with specialized capabilities for AI). Combined, the LillyPod (~1,000 GPUs) yields ~9 EFLOPS (exaFLOPS) of AI-specific computation, while Roche's 3,500 GPUs are presumably on the order of 30+ EFLOPS. This dwarfs typical HPC centers used by pharma a few years ago (10–100 GPUs). Industry sources note these deployments are among the **largest private supercomputers for commercial R&D anywhere**.
- **Results and Productivity:** Hard metrics on improved productivity are not available publicly (no one discloses "AI saved x months"). However, anecdotal reports hint at specific gains. For example, Roche claims its Lab-in-the-Loop (started 2019) shortens cycles for model retraining. Eli Lilly reported in 2023 that an AI-derived lead optimization cut a specific project's timeline by ~50%. Outside pharma, Insilico famously designed an inhibitor in 45 days vs 18 months traditionally (though sometimes these claims mix marketing). In any case, the consensus is that AI speeds certain tasks by factors of 5–10 or more, particularly in ideation and pre-screening.
- **Risks of Overinvestment:** Some analysts caution that a "hype bubble" may be forming. Gartner predicted AI as an enterprise productivity super-boon, but by its usual hype cycle, a "trough of disillusionment" could follow if models underperform or integration is hard (www.linkedin.com) (www.chemdiv.com). McKinsey describes organizations pursuing gen AI in a decentralized manner, use case by use case (McKinsey analysis). However, those in pharma feel the risk of missing out is higher (a line sometimes heard is "I'd rather spend too much now than be existentially disrupted later").
- **Competitive Landscape:** The aggressive investments can be likened to arms races in other tech sectors. When one player discloses a supercomputer, others often respond (Roche expanded right after Lilly's announcement, for example). This may fuel a spiral of ever-larger deployments. Alternatively, some smaller or mid-sized companies may choose to partner heavily (e.g. outsourcing to AWS + NVIDIA EgX instances) rather than build towers on scrubland.

In summary, the data show an industry rapidly putting **resources (money, compute, and attention)** behind AI. Valuations of AI-drug firms are soaring (e.g. shares of publicly listed Recursion and Ginkgo did well in late 2025). According to the chemdiv piece (www.chemdiv.com), pharma R&D professionals themselves rank AI as

the single greatest factor impacting the industry in 2026. This industry-wide confidence level suggests that deals like Lilly/Nvidia and financing like Earendil's are not outliers, but part of a major strategic pivot.

Case Studies and Examples

To illustrate how AI is applied in real projects, we briefly present a few **case examples** of AI-assisted drug discovery and development:

- **AlphaFold (DeepMind):** While not a direct pharma deal, AlphaFold reshaped the field indirectly. By providing accurate protein structures (for millions of proteins and complexes) at no cost, it accelerates target validation and structure-based design. Companies now often check AlphaFold models first for their targets. AlphaFold's extension to AlphaFold 3 (May 2024) enables predictions of ligand interactions and multi-protein complexes (www.axios.com), further integrating AI into early discovery pipelines.
- **Exscientia – DSP-1181:** On January 30, 2020, Exscientia and Sumitomo Dainippon Pharma announced that a Phase I clinical study of their AI-created candidate DSP-1181 had been initiated in Japan for obsessive-compulsive disorder (joint announcement).
- **Recursion Pharmaceuticals:** Using an image-based AI platform, Recursion has identified new uses for existing drugs and novel targets by screening cell morphology. It illustrates a phenotypic AI approach rather than purely molecular design.
- **Isomorphic Labs – Lilly and Novartis:** In January 2024, Isomorphic Labs announced strategic collaborations with Lilly and Novartis (company announcement).
- **Novartis – Microsoft:** Novartis used cloud AI to predict lymph node outcomes in cancer pathology slides (improving radiotherapy planning). It also integrates Natural Language Processing to summarize literature for R&D teams.
- **BenevolentAI:** Its researchers identified baricitinib as a potential way to reduce coronavirus infection of lung cells (primary research).
- **COVID-19 Drug Screening:** During the pandemic, multiple AI teams (e.g., Atomwise, Benevolent) ran rapid screening of repurposed drugs. Though no immediate blockbuster emerged, these efforts validated AI throughput.

These cases illustrate **diverse AI modalities**: structure prediction, generative design, knowledge mining, and image analysis. The examples do not establish successful clinical or investment outcomes.

Note: It's important not to oversell. Many early AI projects in pharma quietly fail (e.g. some AI-predicted leads turn out not to have good ADMET, or algorithms need retraining on proprietary data). We acknowledge a natural selection: the ones that work become case studies and drive investment, while others quietly shutter or pivot.

Regulatory and Ethical Considerations

The deployment of AI in pharma raises regulatory and ethical issues that companies must navigate:

- **Regulatory Guidance:** On January 6, 2025, FDA issued draft guidance with nonbinding recommendations on AI used to generate information supporting regulatory decisions about drug or biologic safety, effectiveness, or quality. The draft excludes AI used solely for drug discovery. On January 14, 2026, FDA and EMA released 10 common guiding principles for AI used to generate evidence across the drug product life cycle (FDA–EMA announcement).
- **Data Privacy:** Pharma AI often requires vast patient data (genomics, health records). Maintaining privacy (HIPAA in US, GDPR in EU) is critical. Lilly's mention of NVIDIA FLARE federated learning (www.linkedin.com) is one solution (sharing model weights instead of raw data). Other initiatives like the All of Us Research Program in NIH or private data lakes highlight the need for encryption and thresholding in multi-party AI. Some companies are exploring synthetic data to train AI without risking patient identifiability.
- **Intellectual Property:** In the United States, USPTO's Assignment Center supports transfers of patent ownership (USPTO assignment guidance). For AI-assisted inventions, U.S. inventorship analysis focuses on the human contribution to conception, regardless of the technology used as a tool (USPTO inventorship guidance).
- **AI Reliability and Transparency:** Black-box ML models can make unpredictable errors. Regulators and scientists are concerned about "hallucinations" or artifacts in AI output. Hence, companies are building in "verifiable pipelines" with multiple steps (e.g., model propose compound, then another model or experiment checks stability) (www.linkedin.com). The industry is aware that demonstrating reproducibility (e.g., similar model output on repeated runs) is key for acceptance (business20channel.tv).
- **Bias and Fairness:** In clinical AI, bias (especially in patient risk models) is well-known. For R&D, one bias risk is focusing too much on Western-population data, leading to drugs less optimized for diverse genetics. Companies might counter this by training models on pan-ethnic datasets or internal diversity data. Ethical reviews may be needed when using AI for patient selection in trials.
- **Employment and Skills:** Automation of some tasks (like initial molecule screening) could threaten certain research jobs, although new roles (AI-savvy chemists, data scientists) are created. Companies are investing in training existing staff (e.g. Deloitte's recommendation for leadership mandates and "no-regret bets" in AI (www.deloitte.com)). Overall, the aim is augmentation, not replacement of human scientists, but reskilling will be necessary.
- **Biosecurity (Dual Use):** Generative AI can design novel bioactive molecules. This has raised alarms that the same tools for creating drugs could design toxins or enhanced pathogens. A recent scholarly review warns of this **dual-use dilemma** (www.frontiersin.org). The life sciences community (and cybersecurity bodies) is discussing safeguards: for example, withholding runway AI models from open access, employing model "watermarks" to detect malicious use, and international agreements on secure sharing. In practice, pharma companies must ensure labs using AI also commit to ethical guidelines. Some funders now require dual-use statements (as mentioned in Frontiers review (www.frontiersin.org)).

- **Ethical AI Principles:** Major Pharma companies have started publishing AI ethics frameworks (e.g. commitments to safe and beneficial AI). These often echo high-level principles: privacy, security, human oversight, fairness. For example, Novartis in late 2025 published an ethical guidelines document that explicitly mentions respecting patient data and sharing learnings responsibly. Such guidelines are partly in response to public and investor scrutiny of AI.
- **Democratization vs Centralization:** There is debate whether deep AI R&D should be concentrated in a few rich players (who can afford exascale computing), or if consortium models will develop (e.g. nonprofit academies or alliances building shared infrastructure). The Cambridge-1 example is a compromise: multiple pharma and public research can use the same machine. One concern is access: Will startups and mid-sized firms be left behind? Cloud providers partly address that by offering specialized AI platforms to small companies at scaled pricing.

In summary, **governance of AI in pharma** is in flux. Companies are proactively engaging with regulators and policymakers to shape sensible rules. The business case (improving patients' lives faster) often aligns with ethical imperatives, but the technology's power demands vigilance. Big pharma's decision to invest billions into AI will inevitably invite scrutiny to ensure that powerful new drug-discovery tools are used responsibly.

AI Partnerships and Ecosystem Trends

Beyond the highlighted deals, the pharma–tech ecosystem in early 2026 shows several patterns:

- **Big Tech Partnerships:** Besides NVIDIA, major cloud/AI companies (Microsoft, Amazon, Google, Anthropic) have explicitly tailored offerings for life sciences (business20channel.tv). On top of this, model companies like OpenAI have begun to market healthcare-specific AI (e.g. GPT-4 with end-to-end encryption for medical records). Each of the big pharma companies works with multiple tech partners:
- **Microsoft:** Partnership with Novartis, GSK, J&J (for research and cloud).
- **AWS:** Deals with Amgen, Johnson & Johnson, and genomic data collaborations.
- **Google/Anthropic:** Working with health systems and some pharma on curated data centers.
- **AI startups:** Google's DeepMind with multiple pharma on healthcare AI (e.g. partner in UK).
- **NVIDIA and AMD:** AMD scheduled an initial 1 GW Instinct MI450 GPU rollout for July–December 2026 (AMD announcement).
- **Cloud vs On-Prem:** We see a hybrid approach. Even Roche, which touts on-prem expansions, still uses a mix of on-prem and cloud (www.roche.com). Many companies keep precious IP and heavy compute in-house, but will burst to the cloud for peak loads. Cloud providers thus win deals to build "pharma grade clouds" and get recurring revenue from usage and managed services. An IDC report notes that pharma CIOs budget not just for AI R&D, but for compliance engineers and cloud architects (close-loop governed AI).

- **Startup Fintech Analogy:** Some commentators say the biotech sector is entering a “Digital Pharma 2.0” era analogous to fintech in banking. New AI platforms stand alongside legacy “big pharma”, and there is realignment (acquisitions of AI firms by pharma, or pharma equity stakes in AI companies). For instance, Roche owns a stake in Recursion and has collaborated with Moderna on AI cell factories. Analogous to how Baidu/Tencent invested in financial tech, BigTech is investing in healthcare AI (e.g. Apple’s health sensors, Google’s AI for diabetology, Amazon’s PillPack+AI stable).
- **Open Science Accelerators:** Many AI breakthroughs in pharma started in academia (DeepMind, academic AI labs). Now companies are sponsoring more university labs and consortia for open technical advances. Pharma backing of consortia (like the Machine Learning for Pharma workshops, or the recently launched UK Institute for Pharmetrics AI, etc.) helps with recruiting talent and shaping academic curriculum. This ecosystem ensures a pipeline of skilled researchers and cross-pollination of ideas.
- **Software Ecosystem:** Vendors are evolving to support pharma: by 2026, large chem/biological software suites (Schrödinger, Biovia, etc.) have integrated ML modules. New entrants (Benchling co-developed ML tools with Amazon, chemical databases integrated with GPT-like interfaces). This means pharma researchers often use plug-in AI in familiar interfaces.
- **Global Perspective:** Developed-world pharma dominates these deals, but developing economies are keen. Chinese companies (like Innovent, BeiGene) are quietly building AI teams. Indian pharma (with large generics firms) is investing more in AI for process optimization. Governments are noticing: the EU’s Horizon Europe program has a multi-billion Euro AI in health initiative (2025–2027 funding).

Implications and Future Directions

Looking ahead, the current deals and investments suggest several trajectories:

- **Acceleration of Drug Discovery Pipelines:** If Lilly/NVIDIA achieves its goals, we may see significantly shorter timelines from target identification to first-in-human doses. It may also enable on-demand discovery: e.g., reacting to emerging pathogen outbreaks by running *real-time* generation of vaccine candidates via AI.
- **Rise of “AI-Designed Products”:** Successful AI-designed molecules (or biologics) reaching market will validate the model. We should watch for the first FDA approval of a wholly AI-designed drug (likely a small molecule first). This would have huge precedent effects. Already, in 2023, Lilly and researchers published that an AI-designed compound for TSLP (an asthma target) acted as predicted in animals, hinting one day of co-founded AI molecules.
- **Standardization of Workflows:** As one article noted, pharma is moving from experimentation to production use of AI (business20channel.tv). We expect that by 2027-2030, companies will have standardized AI-QC steps (like software engineers do CI/CD pipelines) in R&D. AI might become a routine tool for medicinal chemists, akin to how ordering a BLAST sequence search is today. New roles like “AI pharmacologist” might emerge.

- **Broadening Beyond R&D:** While most focus is on discovery, AI will further permeate clinical trials (e.g. adaptive trial designs using Bayesian AI), supply chain (predictive logistics), and even marketing (AI-driven digital outreach). The Lilly/Nvidia announcement also hints at exploring clinical and commercial use cases (investor.lilly.com). Regulators will be developing guidelines for each domain (FDA already considers AI in diagnostics and devices).
- **Economic Restructuring:** Big financial players (pharma M&A teams, VCs, other corporates) are factoring AI into valuations. A biotech that uses AI effectively may be seen as more valuable or less risky. Conversely, companies failing to adopt AI might see lower growth forecasts. Venture investors might start specialized “AI biotech” funds, while large pharma may undergo more restructuring (we’ve already seen initial pharma workforce reductions followed by re-hiring in digital areas).
- **Open Questions:** Key unknowns remain. Will AI lead to a glut of new drug candidates, intensifying competition? Or will it simply make development marginally faster? How will insurance and payers respond to AI-discovered therapies (will they trust claims better if an AI model vetted them)? The legal landscape for AI patents and liability is unsettled. If an AI-designed drug causes unforeseen side effects, who is responsible? These will be tested as prototypes move through trials.
- **Comparison to Other Industries:** The scale of investment is reminiscent of other tech transformations. Some have likened it to the cloud computing race of the 2010s or the microchip boom of the 1960s. The “$1B lab” term is reminiscent of historical industrial labs (e.g. AT&T Bell Labs), implying a trust in R&D labs worth billions upfront.
- **Sustainability:** Energy use of massive AI systems is non-trivial. Companies must also consider the carbon footprint of their data centers. Nvidia and others argue the efficiency of modern chips mitigates this, and that the human lives saved justify the cost. But sustainability commitments from pharma (e.g. net-zero goals) may require attention to green computing (hydrogen cooling, renewable-powered data centers) as part of this push.

Conclusion

The developments covered through **April 2026** mark a pivotal moment for AI in pharmaceuticals. The two signature events – the Lilly–NVIDIA $1B co-innovation lab and Earendil’s $787M funding – exemplify the industry’s **“all-in”** attitude. In each, the narrative is clear: AI is not a peripheral tool but a core driver to be funded on par with labs and machinery.

Our analysis has shown that:

- **The Lilly–NVIDIA co-innovation lab** is a concrete realization of a long-held vision to fuse AI and biology. Its success (and that of competitors like Roche) will demonstrate whether AI can indeed upscale hypothesis testing from thousands to billions of candidates (www.linkedin.com). If these initiatives yield new drug candidates faster, they will reshape R&D cycles permanently.
- **Earendil’s financing** underscores the viability and investor confidence in AI-first biotech. Should Earendil deliver even a handful of new biologics, it will spark a rush of similar deals. If not, it will be a cautionary tale on not conflating funding with discovery.

- **Industry-wide infrastructure investments** suggest we are entering an era where computational power is as critical to pharma as chemical reagents. This is an arms race in computing horsepower. The first companies to master this (and integrate it well with scientific know-how) may gain a decisive edge. But the risk of rapid technological change also means ongoing upgrade costs: e.g. Lilly might need to refresh its pod in a couple years for newer chips (the Xilinx fallacy of needing to constantly invest).

For stakeholders, the findings are:

- **Pharma Executives:** The competitive landscape demands strategic commitment to AI. This involves not just tech partnerships, but culture change, data governance, and new talent pipelines. Interim success metrics should be set (e.g. speed of lead validation) to justify the expenditures.
- **Investors:** The valuations of AI-biotech firms will remain hot if their pipelines progress. However, due diligence is critical: what's the data behind an AI claim? Key inflection points will be clinical trial results from AI-designed drugs.
- **Technologists:** There is an open field for innovation. Domain-specific models (like NVIDIA BioNeMo, or Google's Med-PaLM for chemistry) will keep emerging. Also, improvements in federated learning may allow even tighter collaboration without breaching IP.
- **Regulators and Policymakers:** The urgency is to strike a balance between enabling innovation and ensuring safety. The FDA's recent steps are a blueprint. International cooperation (e.g. ICH guidelines for AI in drugs) would be beneficial. Clear frameworks for clinical validation of AI hits are needed.

Future Research Directions

This report's scope was deals and infrastructure. Future work could dive deeper into:

- **Technical performance:** How exactly do BioNeMo models compare to traditional docking? Are we seeing AI predictions translate reliably into lab results?
- **Economic modeling:** Detailed cost-benefit simulations of AI adoption in R&D (e.g. Monte Carlo analysis of project outcomes with vs without AI).
- **Outcomes Tracking:** Gathering statistics on how AI-designed molecules fare in clinical trials relative to conventionally discovered ones.
- **Ethics/Policy:** Further studies on AI's dual-use risk mitigation, and public attitudes to AI in medicine.

Final Thoughts

We have entered a new chapter in biopharma. If past decades characterized by marginal improvements and consolidation, the late 2020s may be defined by **computational biotechnology**. The Lilly–NVIDIA and Earendil stories are just two high-profile chapters. What unfolds could be the rewriting of pharmaceutical R&D norms.

Indeed, the stakes are high: the world's aging population and persistent disease burdens demand better, faster therapies. AI offers unprecedented tools, but only time will tell how effectively science can wield them. In any event, the massive investments we documented here indicate that **Big Pharma's leaders are betting big**. They are placing infrastructure and capital on the line in the hope that *thinking machines* will help think their way out of the productivity crisis in drug discovery.

The race is on — and the deals covered through April 2026 suggest it is entering a high-gear phase.

References

All claims in this report are supported by publicly available sources, including corporate press releases, industry news articles, and analyst reports. Key references include:

- Eli Lilly press release (Jan 12 2026); FierceBiotech and Yahoo Finance coverage of Lilly–NVIDIA lab.
- Industry analysis of LillyPod (NVIDIA DGX SuperPOD).
- Roche press release on NVIDIA AI factory (Mar 16 2026).
- Pharmaceutical news on Earendil's funding (BioSpace, PharmaLive/Pharmalife, ChemDiv).
- Bloomberg report on Earendil IPO plans.
- NVIDIA blog posts (Lilly's largest AI factory) and NVIDIA Cambridge-1 supercomputer.
- DCD news on Mitsui Tokyo-1.
- Business 2.0 news on cloud/AI in life sciences.
- FDA guidance announcement.
- Deloitte report on AI value.
- Axios news on AlphaFold 3.
- Scholarly review on AI biosecurity risks.
- Other sources as cited inline.

Sources are cited through inline hyperlinks, such as investor.lilly.com.

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. https://investor.lilly.com/news-releases/news-release-details/nvidia-and-lilly-announce-co-innovation-ai-lab-reinvent-drug
2. https://www.linkedin.com/pulse/weekly-market-intelligence-bulletin-march-13-20-2026-global-xhunga-6hyce
3. https://www.biospace.com/press-releases/earendil-labs-announces-787-million-in-financing-to-scale-ai-driven-biologics-discovery-and-development
4. https://www.chemdiv.com/company/media/pharma-news/2026/earendil-labs-lands-787m-to-accelerate-ai-biologics-development-push
5. https://www.pharmalive.com/backed-by-sanofi-pfizer-earendil-bags-787m-for-ai-driven-biologics-design
6. https://www.bloomberg.com/news/articles/2026-03-13/ai-drug-discovery-startup-earendil-is-said-to-consider-hong-kong-ipo
7. https://www.roche.com/media/releases/med-cor-2026-03-16
8. https://nvidianews.nvidia.com/news/nvidia-building-uks-most-powerful-supercomputer-dedicated-to-ai-research-in-healthcare
9. https://www.datacenterdynamics.com/en/news/mitsui-co-to-deploy-nvidia-supercomputer-for-generative-ai-drug-discovery
10. https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/value-of-genai-in-pharma.html
11. https://business20channel.tv/aws-and-microsoft-lead-ai-as-pharma-tech-evolves-in-2026-21-01-2026
12. https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals
13. https://www.axios.com/2024/05/09/google-deepmind-ai-new-alphafold-3

14. https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-product-submissions
15. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1537471/full
16. https://www.sumitomo-pharma.com/news/assets/pdf/ene20200130.pdf
17. https://wifitalents.com/ai-pharmaceutical-industry-statistics
18. https://novartis.gcs-web.com/node/10196
19. https://www.axios.com/2025/01/28/davos-embracing-ai-legacy-industries
20. https://www.deloitte.com/content/dam/assets-zone3/us/en/docs/industries/life-sciences-health-care/2024/us-realizing-transformative-value-from-ai-and-genai-in-life-sciences-040924.pdf
21. https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai
22. https://blogs.nvidia.com/blog/lilly-ai-factory-live
23. https://www.prnewswire.com/news-releases/earendil-labs-announces-strategic-collaboration-with-sanofi-to-discover-bispecific-antibodies-for-autoimmune-diseases-302652305.html
24. https://www.streetinsider.com/PRNewswire/Earendil%2BLabs%2BAnnounces%2BFirst%2BPatient%2BDosed%2Bin%2Ba%2BPhase%2BIIa%2BTrial%2Bof%2Ba%2BHalf-life%2BExtended%2BAnti-TL1A%2BAntibody%2B%28HXN-1001%29%2Bin%2BPatients%2Bwith%2BUlcerative%2BColitis/26262333.html?classic=1
25. https://www.sanofi.com/assets/dotcom/content-app/publications/half-year-financial-reports/Half-year-financial-report-2025.pdf
26. https://www.prnewswire.com/news-releases/earendil-labs-announces-787-million-in-financing-to-scale-ai-driven-biologics-discovery-and-development-302719748.html
27. https://www.towardshealthcare.com/insights/ai-in-pharmaceuticals-market-sizing
28. https://blogs.nvidia.com/blog/generative-ai-supercomputer-pharmaceutical-industry
29. https://www.itpro.com/infrastructure/nvidia-announces-new-supercomputers-and-an-open-model-family-for-science-at-sc-2025
30. https://insilico.com/blog/series_d_round
31. https://markets.financialcontent.com/wral/article/bizwire-2021-4-27-exscientia-announces-investment-of-up-to-525m
32. https://www.mckinsey.com/industries/life-sciences/our-insights/scaling-gen-ai-in-the-life-sciences-industry
33. https://www.isomorphiclabs.com/articles/isomorphic-labs-kicks-off-2024-with-two-pharmaceutical-collaborations
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7137985
35. https://www.fda.gov/media/184830/download
36. https://content.govdelivery.com/accounts/USFDA/bulletins/4045c84
37. https://www.uspto.gov/patents/maintain/patents-assignments-change-search-ownership
38. https://www.uspto.gov/initiatives/artificial-intelligence/faqs
39. https://newsroom.amd.com/news/amd-and-openai-announce-strategic-partnership-to-d

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore AI enablement, pharma and biotech software development, data engineering and BI, and Veeva services. Contact IntuitionLabs to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: https://intuitionlabs.ai

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.